Heteroresistance of Cryptococcus gattii to fluconazole.
We analyzed 71 clinical and environmental Cryptococcus gattii strains that had been isolated before or after the advent of azole antifungals to determine their level of heteroresistance to fluconazole (LHF). All strains of C. gattii manifested heteroresistance, with LHFs that ranged between 4 microg/ml and 32 microg/ml. A considerably higher proportion of the C. gattii strains (86%) than Cryptococcus neoformans strains (46%) exhibited LHFs that were > or =16 microg/ml. No significant correlation was observed between the molecular type or serotypes of strains and their respective LHF. The strains which expressed a higher LHF were also more resistant to xenobiotics than the strains with a low LHF, and the level of resistance to xenobiotics was significantly higher than that reported for C. neoformans. The heteroresistant subpopulation, whose level of drug resistance had been raised in a stepwise manner to 64 microg/ml, reverted to the original LHF upon daily transfers in drug-free medium. Importantly, the strains with high LHFs were significantly more virulent than those with low LHFs. Since all the clinical isolates that had not been exposed to azole drugs as well as the environmental strains manifested heteroresistance to fluconazole, heteroresistance of C. gattii to azoles is an intrinsic mechanism as in C. neoformans and is associated with the strain's virulence.
Varma
A
A
Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Kwon-Chung
K J
KJ
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology; D056285:Cryptococcus gattii / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D003455:Cryptococcus neoformans / Q000187:drug effects; D025141:Drug Resistance, Fungal; D004783:Environmental Microbiology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D012703:Serotyping; D013045:Species Specificity; D014774:Virulence
D000935:Antifungal Agents; D015725:Fluconazole
Antimicrob Agents Chemother. 1997 Apr;41(4):748-51
9087482
Infect Dis Clin North Am. 2002 Dec;16(4):837-74, v-vi
12512184
Emerg Infect Dis. 2008 May;14(5):755-62
18439357
Science. 2006 Jul 21;313(5785):367-70
16857942
J Clin Microbiol. 2004 Oct;42(10):4815-7
15472349
J Med Vet Mycol. 1992;30(1):61-9
1573522
Clin Infect Dis. 1998 Jan;26(1):186-7
9455533
FEMS Yeast Res. 2006 Jun;6(4):574-87
16696653
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17258-63
15572442
Clin Microbiol Infect. 2008 Jul;14(7):727-30
18558948
Antimicrob Agents Chemother. 2001 Jan;45(1):52-9
11120944
Microbiology (Reading). 2006 Dec;152(Pt 12):3723-3731
17159224
Clin Infect Dis. 1995 Jul;21(1):28-34; discussion 35-6
7578756
Antimicrob Agents Chemother. 2009 Jul;53(7):2804-15
19414582
Med Mycol. 2009;47(6):561-70
19462334
J Antimicrob Chemother. 2007 Aug;60(2):312-6
17553813
Nature. 2005 Oct 27;437(7063):1360-4
16222245
FEMS Yeast Res. 2006 Jun;6(4):625-35
16696659
Clin Infect Dis. 1995 Mar;20(3):611-6
7756484
Infect Immun. 1992 May;60(5):1869-74
1563776
Antimicrob Agents Chemother. 1998 Oct;42(10):2584-9
9756759
Clin Infect Dis. 1994 Nov;19(5):975-6
7893896
Clin Infect Dis. 2000 Aug;31(2):499-508
10987712
J Clin Microbiol. 1990 Jul;28(7):1642-4
2199524
Emerg Infect Dis. 2003 Feb;9(2):189-95
12603989
J Clin Microbiol. 1997 Dec;35(12):3340-2
9399553
FEMS Microbiol Lett. 2000 Jun 1;187(1):41-5
10828398
N Engl J Med. 1995 Mar 16;332(11):700-5
7854376
Clin Infect Dis. 1996 Dec;23(6):1337-8
8953097
Clin Infect Dis. 1997 Oct;25(4):908-10
9356806
Int J STD AIDS. 1995 Sep-Oct;6(5):353-5
8547418
Microbiology (Reading). 2001 Apr;147(Pt 4):891-907
11283285
Mycologia. 1976 Jul-Aug;68(4):943-6
790173
Electrophoresis. 1999 Jun;20(8):1790-9
10435451
J Clin Microbiol. 1982 Mar;15(3):535-7
7042750
Genetics. 2006 Apr;172(4):2223-38
16322524